Skip to main content
. 2020 Apr 3;13:1023–1033. doi: 10.2147/DMSO.S237948

Table 1.

Baseline Patient Characteristics

Overall Continuers [A] Interrupters [B] Discontinuers [C] p-value [A vs B] p-value [A vs C] p-value [B vs C]
(n = 154) (n = 52) (n = 52) (n = 50)
Age
 Mean (SD) 51.4 (16.4) 63.8 (12.5) 43.2 (14.0) 47.2 (14.8) <0.01 <0.01 0.16
Male, n (%) 80 (51.9%) 28 (53.8%) 32 (61.5%) 20 (40.0%) 0.43 0.16 0.03
Race/ethnicity, n (%)*
 White 124 (80.5%) 47 (90.4%) 37 (71.2%) 40 (80.0%) 0.01 0.14 0.30
 Black or African American 23 (14.9%) 6 (11.5%) 10 (19.2%) 7 (14.0%) 0.28 0.71 0.48
 Hispanic 9 (5.8%) 1 (1.9%) 3 (5.8%) 5 (10.0%) 0.31 0.08 0.43
 American Indian or Alaska Native 3 (1.9%) 0 (0.0%) 0 (0.0%) 3 (6.0%) 0.07 0.07
 Asian 5 (3.2%) 0 (0.0%) 4 (7.7%) 1 (2.0%) 0.04 0.31 0.18
Education level, n (%) 0.01 0.12 0.61
 Less than high school 1 (0.6%) 0 (0.0%) 1 (1.9%) 0 (0.0%)
 High school or equivalent 25 (16.2%) 13 (25.0%) 5 (9.6%) 7 (14.0%)
 Some college 44 (28.6%) 17 (32.7%) 12 (23.1%) 15 (30.0%)
 Associate’s degree or equivalent 20 (13.0%) 4 (7.7%) 7 (13.5%) 9 (18.0%)
 College degree 64 (41.6%) 18 (34.6%) 27 (51.9%) 19 (38.0%)
  Bachelor’s degree or equivalent 47 (30.5%) 9 (17.3%) 23 (44.2%) 15 (30.0%)
  Graduate degree 17 (11.0%) 9 (17.3%) 4 (7.7%) 4 (8.0%)
Employment status, n (%) <0.01 <0.01 0.03
 Working full-time 64 (41.6%) 11 (21.2%) 32 (61.5%) 21 (42.0%)
 Working part-time 15 (9.7%) 2 (3.8%) 6 (11.5%) 7 (14.0%)
 Not employed 5 (3.2%) 1 (1.9%) 2 (3.8%) 2 (4.0%)
 Disabled 14 (9.1%) 2 (3.8%) 2 (3.8%) 10 (20.0%)
 Retired 41 (26.6%) 29 (55.8%) 4 (7.7%) 8 (16.0%)
 Student 5 (3.2%) 0 (0.0%) 5 (9.6%) 0 (0.0%)
 Homemaker 10 (6.5%) 7 (13.5%) 1 (1.9%) 2 (4.0%)
Living with a spouse/partner, n (%) 105 (68.2%) 35 (67.3%) 37 (71.2%) 33 (66.0%) 0.67 0.89 0.58
Health insurance coverage when initiating basal insulin, n (%)
 Medical care 137 (89.0%) 51 (98.1%) 44 (84.6%) 42 (84.0%) 0.02 0.01 0.93
 Prescription drugs 138 (89.6%) 50 (96.2%) 47 (90.4%) 41 (82.0%) 0.24 0.02 0.22
Years since first T2DM diagnosis
 Mean (SD) 8.6 (9.3) 9.9 (7.0) 8.1 (11.2) 7.8 (9.5) 0.32 0.21 0.89
 Median [IQR] 6.0 [3.0–12.0] 10.0 [4.0–14.5] 6.0 [3.0–10.0] 4.5 [2.0–10.0]
Mode of delivery of basal insulin initiated, n (%) 0.57 0.15 0.50
 Pen (prefilled/disposable) 97 (63.0%) 37 (71.2%) 32 (61.5%) 28 (56.0%)
 Pen (reusable) & cartridge 20 (13.0%) 4 (7.7%) 6 (11.5%) 10 (20.0%)
 Vial and syringe 37 (24.0%) 11 (21.2%) 14 (26.9%) 12 (24.0%)
Prior use of antidiabetic medications to treat T2DM, n (%)
 Any prior use of antidiabetic medication 118 (76.6%) 43 (82.7%) 45 (86.5%) 30 (60.0%) 0.59 0.01 <0.01
 Oral antidiabetics 105 (68.2%) 41 (78.8%) 37 (71.2%) 27 (54.0%) 0.37 <0.01 0.07
 Injectables other than insulin 30 (19.5%) 8 (15.4%) 15 (28.8%) 7 (14.0%) 0.10 0.84 0.07

Notes: Continuers had no gaps of ≥7 days in basal insulin treatment. Interrupters stopped basal insulin for ≥7 days within the first 6 months after initiation and since restarted basal insulin. Discontinuers stopped using basal insulin for ≥7 days within the first 6 months after initiation and had not restarted basal insulin by the time of the survey. *One respondent declined to answer this question. Categories not listed in the table had 0 respondents (“Native Hawaiian or other Pacific Islander”, “Other”). P-values were calculated using t-tests for continuous variables and chi-square tests or Fisher’s exact tests for categorical variables. P<0.05 was considered statistically significant.